Do analysts prefer NEUP or SNOA?

Neuphoria Therapeutics currently has a consensus price target of $21.00, indicating a potential upside of 434.35%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Neuphoria Therapeutics is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuphoria Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend SNOA or TVRD?

Tvardi Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 800.00%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Do analysts rate KZIA or SNOA?

Novogen currently has a consensus target price of $25.80, indicating a potential upside of 114.84%. Given Novogen's stronger consensus rating and higher probable upside, equities analysts clearly believe Novogen is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, KZIA or SNOA?

Sonoma Pharmaceuticals has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 660.50 -$13.41M N/A N/A Sonoma Pharmaceuticals $19.53M 0.28 -$3.17M -$1.89 N/A

Do analysts prefer ATOS or SNOA?

Atossa Genetics presently has a consensus target price of $20.33, indicating a potential upside of 755.78%. Given Atossa Genetics' stronger consensus rating and higher probable upside, research analysts plainly believe Atossa Genetics is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate CLRB or SNOA?

Cellectar Biosciences currently has a consensus price target of $11.00, indicating a potential upside of 335.82%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Cellectar Biosciences is more favorable than Sonoma Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Sonoma Pharmaceuticals (SNOA) Competitors

$1.13 -0.07 (-5.83%)

As of 03:52 PM Eastern

Compare

SNOA vs. NEUP, TVRD, KZIA, ATOS, and CLRB

Should you buy Sonoma Pharmaceuticals stock or one of its competitors? MarketBeat compares Sonoma Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sonoma Pharmaceuticals include Neuphoria Therapeutics (NEUP), Tvardi Therapeutics (TVRD), Novogen (KZIA), Atossa Genetics (ATOS), and Cellectar Biosciences (CLRB).

How does Sonoma Pharmaceuticals compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

In the previous week, Neuphoria Therapeutics had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 1 mentions for Neuphoria Therapeutics and 0 mentions for Sonoma Pharmaceuticals. Neuphoria Therapeutics' average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Neuphoria Therapeutics	Neutral
Sonoma Pharmaceuticals	Neutral

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Neuphoria Therapeutics has higher earnings, but lower revenue than Sonoma Pharmaceuticals. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65M	1.36	-$370K	-$11.06	N/A
Sonoma Pharmaceuticals	$19.53M	0.28	-$3.17M	-$1.89	N/A

Neuphoria Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -16.26%. Sonoma Pharmaceuticals' return on equity of -43.95% beat Neuphoria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-76.93%	-54.76%
Sonoma Pharmaceuticals	-16.26%	-43.95%	-11.27%

Neuphoria Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

Neuphoria Therapeutics currently has a consensus price target of $21.00, indicating a potential upside of 434.35%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Neuphoria Therapeutics is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Neuphoria Therapeutics beats Sonoma Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Tvardi Therapeutics?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Sonoma Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are held by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tvardi Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -16.26%. Sonoma Pharmaceuticals' return on equity of -43.95% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-16.26%	-43.95%	-11.27%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Sonoma Pharmaceuticals has higher revenue and earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$19.53M	0.28	-$3.17M	-$1.89	N/A
Tvardi Therapeutics	$7.14M	2.63	-$18.21M	-$3.10	N/A

Tvardi Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 800.00%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Tvardi Therapeutics had 4 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 0 mentions for Sonoma Pharmaceuticals. Tvardi Therapeutics' average media sentiment score of 0.16 beat Sonoma Pharmaceuticals' score of 0.00 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sonoma Pharmaceuticals	Neutral
Tvardi Therapeutics	Neutral

Summary

Tvardi Therapeutics beats Sonoma Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Novogen?

Novogen (NASDAQ:KZIA) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Novogen currently has a consensus target price of $25.80, indicating a potential upside of 114.84%. Given Novogen's stronger consensus rating and higher probable upside, equities analysts clearly believe Novogen is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Novogen has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -16.26%. Novogen's return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Sonoma Pharmaceuticals	-16.26%	-43.95%	-11.27%

30.9% of Novogen shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sonoma Pharmaceuticals has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	660.50	-$13.41M	N/A	N/A
Sonoma Pharmaceuticals	$19.53M	0.28	-$3.17M	-$1.89	N/A

In the previous week, Novogen had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 1 mentions for Novogen and 0 mentions for Sonoma Pharmaceuticals. Novogen's average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Novogen	Neutral
Sonoma Pharmaceuticals	Neutral

Novogen has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Summary

Novogen beats Sonoma Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Atossa Genetics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -16.26%. Sonoma Pharmaceuticals' return on equity of -43.95% beat Atossa Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-84.91%	-72.36%
Sonoma Pharmaceuticals	-16.26%	-43.95%	-11.27%

In the previous week, Atossa Genetics had 2 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 2 mentions for Atossa Genetics and 0 mentions for Sonoma Pharmaceuticals. Atossa Genetics' average media sentiment score of 0.00 equaled Sonoma Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Atossa Genetics	Neutral
Sonoma Pharmaceuticals	Neutral

Atossa Genetics presently has a consensus target price of $20.33, indicating a potential upside of 755.78%. Given Atossa Genetics' stronger consensus rating and higher probable upside, research analysts plainly believe Atossa Genetics is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sonoma Pharmaceuticals has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.21	N/A
Sonoma Pharmaceuticals	$19.53M	0.28	-$3.17M	-$1.89	N/A

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Atossa Genetics has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

Summary

Atossa Genetics beats Sonoma Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Sonoma Pharmaceuticals compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Cellectar Biosciences has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -16.26%. Sonoma Pharmaceuticals' return on equity of -43.95% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Sonoma Pharmaceuticals	-16.26%	-43.95%	-11.27%

Cellectar Biosciences has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Sonoma Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

In the previous week, Cellectar Biosciences had 4 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 4 mentions for Cellectar Biosciences and 0 mentions for Sonoma Pharmaceuticals. Cellectar Biosciences' average media sentiment score of 0.50 beat Sonoma Pharmaceuticals' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectar Biosciences	Neutral
Sonoma Pharmaceuticals	Neutral

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by insiders. Comparatively, 1.0% of Sonoma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Sonoma Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Sonoma Pharmaceuticals	$19.53M	0.28	-$3.17M	-$1.89	N/A

Cellectar Biosciences currently has a consensus price target of $11.00, indicating a potential upside of 335.82%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Cellectar Biosciences is more favorable than Sonoma Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cellectar Biosciences beats Sonoma Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Sonoma Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNOA vs. The Competition

Export

Metric	Sonoma Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.41M	$11.69B	$6.89B	$12.89B
Dividend Yield	N/A	2.73%	2.60%	10.01%
P/E Ratio	-0.60	791.57	280.82	25.46
Price / Sales	0.28	736.44	596.28	91.11
Price / Cash	N/A	71.54	72.11	49.40
Price / Book	1.74	10.85	12.99	6.09
Net Income	-$3.17M	$2.82B	$3.49B	$348.05M
7 Day Performance	2.73%	3.21%	3.43%	4.73%
1 Month Performance	-6.61%	-2.07%	-2.63%	-2.14%
1 Year Performance	-62.46%	193.54%	73.71%	20.85%

Sonoma Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNOA Sonoma Pharmaceuticals	0.4182 of 5 stars	$1.13 -5.8%	N/A	-61.2%	$5.41M	$19.53M	N/A	180	Positive News Upcoming Earnings
NEUP Neuphoria Therapeutics	2.253 of 5 stars	$3.80 -0.3%	$21.00 +452.6%	-50.0%	$20.52M	$15.65M	N/A	N/A
TVRD Tvardi Therapeutics	3.1319 of 5 stars	$2.14 -12.3%	$19.67 +819.0%	-92.3%	$20.07M	$7.14M	N/A	80	Gap Down
KZIA Novogen	1.5358 of 5 stars	$12.10 -4.6%	$25.80 +113.2%	+47.6%	$19.97M	$30K	N/A	12	News Coverage
ATOS Atossa Genetics	1.7877 of 5 stars	$2.31 -4.1%	$20.33 +780.2%	-81.5%	$19.89M	N/A	N/A	8	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNOA) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sonoma Pharmaceuticals (SNOA) Competitors

SNOA vs. NEUP, TVRD, KZIA, ATOS, and CLRB

How does Sonoma Pharmaceuticals compare to Neuphoria Therapeutics?

Summary

How does Sonoma Pharmaceuticals compare to Tvardi Therapeutics?

Summary

How does Sonoma Pharmaceuticals compare to Novogen?

Summary

How does Sonoma Pharmaceuticals compare to Atossa Genetics?

Summary

How does Sonoma Pharmaceuticals compare to Cellectar Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA vs. The Competition

Sonoma Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sonoma Pharmaceuticals (SNOA) Competitors

SNOA vs. NEUP, TVRD, KZIA, ATOS, and CLRB

How does Sonoma Pharmaceuticals compare to Neuphoria Therapeutics?

Does the media favor NEUP or SNOA?

Do institutionals and insiders have more ownership in NEUP or SNOA?

Which has stronger valuation and earnings, NEUP or SNOA?

Is NEUP or SNOA more profitable?

Which has more volatility and risk, NEUP or SNOA?

Do analysts prefer NEUP or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to Tvardi Therapeutics?

Which has more volatility and risk, SNOA or TVRD?

Do insiders & institutionals have more ownership in SNOA or TVRD?

Is SNOA or TVRD more profitable?

Which has preferable earnings & valuation, SNOA or TVRD?

Do analysts recommend SNOA or TVRD?

Does the media refer more to SNOA or TVRD?

Summary

How does Sonoma Pharmaceuticals compare to Novogen?

Do analysts rate KZIA or SNOA?

Is KZIA or SNOA more profitable?

Do institutionals & insiders have more ownership in KZIA or SNOA?

Which has better earnings & valuation, KZIA or SNOA?

Does the media refer more to KZIA or SNOA?

Which has more risk & volatility, KZIA or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to Atossa Genetics?

Is ATOS or SNOA more profitable?

Does the media favor ATOS or SNOA?

Do analysts prefer ATOS or SNOA?

Which has better valuation and earnings, ATOS or SNOA?

Do institutionals and insiders believe in ATOS or SNOA?

Which has more volatility and risk, ATOS or SNOA?

Summary

How does Sonoma Pharmaceuticals compare to Cellectar Biosciences?

Is CLRB or SNOA more profitable?

Which has more risk & volatility, CLRB or SNOA?

Does the media favor CLRB or SNOA?

Do institutionals & insiders hold more shares of CLRB or SNOA?

Which has higher earnings and valuation, CLRB or SNOA?

Do analysts rate CLRB or SNOA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNOA vs. The Competition

Sonoma Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools